These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 12218644)
1. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Csernansky JG; Miller JP; McKeel D; Morris JC Alzheimer Dis Assoc Disord; 2002; 16(3):144-9. PubMed ID: 12218644 [TBL] [Abstract][Full Text] [Related]
2. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
5. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Sjögren M; Davidsson P; Gottfries J; Vanderstichele H; Edman A; Vanmechelen E; Wallin A; Blennow K Dement Geriatr Cogn Disord; 2001; 12(4):257-64. PubMed ID: 11351137 [TBL] [Abstract][Full Text] [Related]
6. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015 [TBL] [Abstract][Full Text] [Related]
7. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Laske C; Stransky E; Fritsche A; Eschweiler GW; Leyhe T Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):80-5. PubMed ID: 18806919 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440 [TBL] [Abstract][Full Text] [Related]
9. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
12. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677 [TBL] [Abstract][Full Text] [Related]
13. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648 [TBL] [Abstract][Full Text] [Related]
14. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185 [TBL] [Abstract][Full Text] [Related]
15. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
17. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]